Production of dose-response plates and cherry-picking are essential steps in early drug discovery to enable testing of many thousands of compounds. Researchers at Novartis are benefitting from the automated plate generation capabilities of two customized systems based on Freedom EVO® 200 platforms, each equipped with an MCA 384, significantly increasing sample throughput to over 10,000 compounds a day.
